Dual-Mode Vasodilator M119 Delivery to Hair Follicle via Dissolving Microneedle for Advanced Alopecia Treatment

Youseong Kim, Yeong Chan Ryu, Hye Su Min, Huisuk Yang, Jeehye Nam, Chisong Lee, Daniel Junmin Um, Miji Kim, Paola Atzei, Rita de Brito Francisco, Reto Naef, Kang Yell Choi, Hyungil Jung

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Finasteride, the most widely used oral alopecia drug, shows several side effects such as hypoactive sexual dysfunction or depression, whereas the topical drug minoxidil demonstrates unsatisfactory efficacy. Thus, there is an increasing need for new alopecia drugs and alternative delivery systems for future alopecia treatment. Researchers have developed dissolving microneedle (DMN), a transdermal drug delivery system, which can be used with minimal invasion. However, DMN has limited application for the alopecia treatment owing to its unsuccessful implantation on the hairy scalp. Here, it is suggested that TOP-M119 (M119), a novel drug acting as a vasodilator in the scalp, and M119-loaded DMN with a specially designed shape can be used for the alopecia treatment. This M119-loaded DMN system is delivered using a newly designed applicator that supports patchless scalp implantation of DMN by microsized pillars designed to prevent accidental skin insertion. Enhanced hair follicle targeting drug delivery and superior alopecia treatment efficacy of specially designed shaped DMN and M119 has been demonstrated through in vitro and ex vivo studies. Moreover, M119-loaded DMN system shows enhanced in vivo efficacy in mouse skin and through expression markers related to hair growth, such as β-catenin, proliferating cell nuclear antigen, MECA 32, and versican.

Original languageEnglish
Article number2200052
JournalAdvanced Therapeutics
Issue number8
Publication statusPublished - 2022 Aug

Bibliographical note

Funding Information:
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (grant number: 2020M3E5D8108104), a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI20C1234), and the Brain Korea 21(BK21) FOUR program. Dr. Hermann Tenor, Esra Lone, and Jaan Strang (TOPADUR Pharma AG) for the PDE activity assay and cGMP measurements in human platelets are thanked.

Publisher Copyright:
© 2022 Wiley-VCH GmbH.

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Pharmacology
  • Pharmaceutical Science
  • Genetics(clinical)
  • Biochemistry, medical
  • Pharmacology (medical)


Dive into the research topics of 'Dual-Mode Vasodilator M119 Delivery to Hair Follicle via Dissolving Microneedle for Advanced Alopecia Treatment'. Together they form a unique fingerprint.

Cite this